Rhythm Pharmaceuticals (RYTM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rhythm Pharmaceuticals faces a business ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have earned an average recommendation of “Moderate Buy ...

Handelsbanken Fonder AB lessened its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 11.9% in the 4th quarter, HoldingsChannel reports. The institutional investor ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

Rhythm announced a strategic partnership agreement with Trispera Pharma Solutions in Turkey.Discover the Best Stocks and Maximize Your ...

Investing.com - Rhythm Pharma (NASDAQ: RYTM) reported third quarter EPS of $-0.76, in line with the analyst estimate of $-0.76.

10 analysts have shared their evaluations of Rhythm Pharmaceuticals RYTM during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed ...

Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its fourth quarter and ...

BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...